

# Impact of STARD on reporting quality of diagnostic accuracy studies in a top Indian Medical Journal: A retrospective survey

Rajashree Yellur<sup>1</sup>, Shabbeer Hassan<sup>Corresp. 2</sup>

<sup>1</sup> Department of Statistics, Manipal University, Manipal Academy of Higher Education, Manipal, India

<sup>2</sup> Institute for Molecular Medicine, University of Helsinki,, University of Helsinki, Helsinki, Finland

Corresponding Author: Shabbeer Hassan  
Email address: shabbeer.hassan@helsinki.fi

Improper reporting of diagnostic studies leads to an incorrect assessment of their clinical performance. STARD (Standards for Reporting of Diagnostic Accuracy Studies) checklist was launched in 2003 with the intention of improving reporting quality in diagnostic accuracy studies. The main aim of this study was to check the extent to which published diagnostic accuracy studies follow the 28-item STARD checklist. We conducted a literature survey of diagnostic studies published in Indian Journal of Medical Research (IJMR) between the years 1995-2013 for the evaluating their reporting quality by checking their adherence to STARD. Relevant studies (N=76) were retrieved from IJMR website and data extraction was performed by two authors simultaneously. A simple pre-post analysis found that there was no overall change in the reporting quality before and after STARD was released. Though some STARD items like description of participant sampling ( $\chi^2 = 5.712$ ,  $p = 0.0169$ ), clinical applicability of study findings ( $\chi^2 = 9.704$ ,  $p = 0.0018$ ) had a significant increase in post-STARD period. To take into account any underlying trend we conducted an interrupted time-series was done. We found a significant increase in the reporting quality after publication of STARD ( $\beta_3 = 0.215 \pm 0.068$ ,  $p = 0.034$ ). The overall reporting quality of diagnostic accuracy studies have improved since the introduction of STARD, however, error/defects in many sections remain as before.

1 **IMPACT OF STARD ON REPORTING QUALITY OF DIAGNOSTIC ACCURACY**  
2 **STUDIES IN A TOP INDIAN MEDICAL JOURNAL: A RETROSPECTIVE STUDY**

3 *Rajashree Yellur, Shabbeer Hassan*

4 **Rajashree Yellur**, MSc Biostatistics, Department of Statistics, Level 6, Health Science Library  
5 Building, Manipal University, Manipal 576104.  
6 Email: rajashreeyellur@gmail.com

7 **Shabbeer Hassan**, FIMM-EMBL PhD student, Institute for Molecular Medicine (FIMM),  
8 University of Helsinki, Finland-00014.  
9 Email: shabbeer.hassan@helsinki.fi

10 **CORRESPONDING AUTHOR**

11 **Shabbeer Hassan**,

12 FIMM-EMBL PhD student, Institute for Molecular Medicine (FIMM), University of Helsinki,  
13 Helsinki, Finland-00014

14 **Email:** shabbeer.hassan@helsinki.fi

15 **Phone:** +358-468437288

## 16 ABSTRACT

17 Improper reporting of diagnostic studies leads to an incorrect assessment of their clinical  
18 performance. STARD (Standards for Reporting of Diagnostic Accuracy Studies) checklist was  
19 launched in 2003 with the intention of improving reporting quality in diagnostic accuracy studies.  
20 The main aim of this study was to check the extent to which published diagnostic accuracy  
21 studies follow the 28-item STARD checklist. We conducted a literature survey of diagnostic  
22 studies published in Indian Journal of Medical Research (IJMR) between the years 1995-2013 for  
23 the evaluating their reporting quality by checking their adherence to STARD. Relevant studies  
24 (N=76) were retrieved from IJMR website and data extraction was performed by two authors  
25 simultaneously. A simple pre-post analysis found that there was no overall change in the reporting  
26 quality before and after STARD was released. Though some STARD items like description of  
27 participant sampling ( $\chi^2 = 5.712$ ,  $p = 0.0169$ ), clinical applicability of study findings ( $\chi^2 = 9.704$ ,  $p$   
28  $= 0.0018$ ) had a significant increase in post-STARD period. To take into account any underlying  
29 trend we conducted an interrupted time-series was done. We found a significant increase in the  
30 reporting quality after publication of STARD ( $\beta_3 = 0.215 \pm 0.068$ ,  $p = 0.034$ ). The overall  
31 reporting quality of diagnostic accuracy studies have improved since the introduction of STARD,  
32 however, error/defects in many sections remain as before.

## 33 INTRODUCTION

34 Diagnostic studies are conducted to evaluate how efficacious a given test is in reference to a  
35 given disorder. A better nomenclature for them however is diagnostic accuracy studies. Here,  
36 accuracy refers to the rate of agreement between the current test under evaluation, known as  
37 index test and a standard test or gold/reference standard. Diagnostic accuracy from such kind of  
38 studies are usually reported as: sensitivity, specificity, likelihood ratio, AUC etc. [Griner et al.,  
39 1984; Metz 1978; Sackett et al., 1991]

40 The clinician uses this information to make decisions whether a given diagnostic test is useful for  
41 a given disorder or not. Hence, badly conducted or reported diagnostic studies would lead to  
42 biased results, which in turn might mislead clinicians endangering patients' lives [Lijmer et al.,  
43 1999].

44 Several factors are known to affect the internal and external validity of diagnostic accuracy  
45 studies. Several reviews [Lijmer et al., 1999; Reid et al., 1995; Plint et al., 2006; Moher et al.,  
46 2001; Turner et al., 2012] which looked at the reporting of diagnostic studies found that several  
47 major elements like design, conduct or analysis are missing and not reported at all.

48 The STARD (Standards for Reporting of Diagnostic Accuracy Studies) statement was published  
49 in 2003 as a public release in 13 reputed biomedical journals. The primary aim was to combat the  
50 growing menace of incomplete reporting and poorly designed diagnostic accuracy studies as  
51 reported by some reviews published before STARD checklist was published [Bossuyt, 2008].  
52 The checklist contains 28 items for inclusion by authors which should be then checked by journal  
53 reviewers.

54 Apart from the checklist, STARD prescribes a flowchart similar to the PRISMA statement which  
55 describes the flow of participant inclusion/exclusion in the study. Till now, around 200 journals  
56 have supported the STARD statement (<http://www.stard-statement.org/>).

57 In the past 20 years many reporting guidelines like CONSORT for randomized controlled trials,  
58 STROBE for observational studies etc. have been introduced. Since then, many researchers have  
59 conducted studies to test the impact of such guidelines on the reporting quality of published  
60 studies but results so far have been conflicting at best.

61 For example, in case of STARD guideline, there have been controversies surrounding its impact  
62 as one study saw a minor increase in the reporting quality after STARD [Smidt et al., 2006]  
63 whereas another study didn't find it to be the case [Wilczynski et al., 2008]. We believe this  
64 controversy might be due to ignoring the underlying time trend underlying the reporting quality  
65 change. To address this issue, we used interrupted time series analysis apart from the normal pre-  
66 post statistical test.

67 We decided to focus on a single medical journal to test the role of STARD in changing if any, the  
68 reporting quality of published diagnostic studies. Indian Journal of Medical Research (IJMR) is  
69 one of India's and in fact one of Asia's best medical journals with more than 100 years of  
70 publication history. It has one of the highest impact factors among Indian medical journals  
71 (<http://www.icmr.nic.in/Publications/IJMR.html>). Because of its widespread reputation and  
72 readership among clinicians we decided to focus our evaluation of the reporting quality of  
73 diagnostic accuracy studies only on IJMR.

## 74 **METHODS**

### 75 **Search Criteria**

76 To identify all the eligible studies, we conducted a PubMed search of IJMR and manually  
77 searched all issues of the journal published during the study period. The keyword used for the  
78 search in Pubmed were (("sensitivity AND specificity" OR "specificit\*" OR "false negative" OR  
79 "accuracy")) AND "Indian Journal of Medical Research"[Journal] with studies restricted/limited  
80 to humans and only those studies with abstracts”.

### 81 **Article Selection**

82 We selected all articles published between January 1999 and December 2013 that were declared  
83 as diagnostic studies or used sensitivity or specificity in their preferred mode of analysis. The  
84 analysis time period was chosen in such a way that it formed an approximate 10-year window  
85 around the release of STARD. We did not select any letters to editors, or review papers. The titles  
86 and abstracts were screened by two of us (SH and RY) working independently of each other and  
87 resolving disagreements by consensus, which led to the selection of 76 articles. The names and  
88 affiliations of the authors and the dates of article acceptance and publication were masked to  
89 minimize evaluation bias by the raters.

### 90 **Data abstraction**

91 We included all 25 items in the STARD checklist along with three additional items from other  
92 published checklists to represent the changing demands of a published article. Each article was  
93 evaluated based on the 28 items of our checklist (Table 1). Further on, each item in the checklist  
94 was evaluated using a three-point rating scale: 1- criteria met, 2 - criteria not met, and 3 - cannot  
95 determine or not relevant. All problems were reviewed by the authors (SH and RY) within  
96 themselves and external faculty from Department of Statistics, Manipal University served as the  
97 final adjudicator. Data was collected using a user-friendly form with EpiData version 3.1.

### 98 **Outcome measure**

99 The primary outcome is a composite score obtained from our checklist defined as the number of  
100 the 28 items properly reported divided by the total number of applicable items. Here total

101 applicable items was found out by subtracting total to the number of non-applicable items for  
102 each article. The score was then expressed in form of a percentage. This study did not require  
103 approval by an ethics committee, since it concerned research publications and not individuals.  
104 The inter-rater agreement for all the information coded from the articles was examined using the  
105 intraclass correlation coefficient (ICC) [Shrout et al., 1979]. The ICC values for the 28 items  
106 related to the diagnostic studies adherence to STARD ranged from 0.83 to 0.989.

## 107 **Data analysis**

108 All the quantitative variables are summarized here as mean (standard deviation) and qualitative  
109 variables as number (percentage). We used a paired t-test to determine whether there was a  
110 change in the outcome before (1995-2002) and after (2004-2013) STARD publication and Mc-  
111 Nemar test for testing change in outcome of certain items within our checklist.

112 Interrupted time series analysis: To address the underneath time trend of the reporting quality  
113 after STARD publication we also conducted an interrupted time-series analysis using a  
114 segmented regression model. The main question was to determine whether STARD had any  
115 impact on the mean score after its publication [Eccles et al., 2003; Ramsay et al., 2003; Wagner et  
116 al., 2002]. We considered two periods, pre (1993-2002) and post- STARD period (2004-2013). In  
117 the model, dependent variable was the checklist score mean and the independent variable was  
118 year considered.

119 The segmented regression model as in [Cochrane ITS study, 2009]:

$$120 \text{ Mean Score} = \text{Constant} + \beta_1 X_1 + \beta_2 X_2 + \beta_3 X_3$$

121 Here the coefficient for 'X<sub>1</sub>' ( $\beta_1$ ) gives the slope of the regression line pre- STARD, coefficient  
122 for 'X<sub>2</sub>' ( $\beta_2$ ) is the change in intercept and coefficient for 'X<sub>3</sub>' ( $\beta_3$ ) provides the change in slope  
123 pre-and post STARD.

124 Therefore, pre STARD: Outcome = constant +  $\beta_1$ \*time and post STARD: Outcome = Constant +  
125  $\beta_1 X_1 + \beta_2 + \beta_3 X_3 = (\text{constant} + \beta_2) + (\beta_1 + \beta_3)$ \*time (as X<sub>1</sub> and X<sub>3</sub> remain the same post STARD).  
126 Therefore, the difference in constant (intercept) pre-and post STARD is  $\beta_2$  and difference in slope  
127 is  $\beta_3$ . The level and trend of pre- STARD segment (1995 -2002) served as the control for the post-  
128 STARD segment (2002- 2013). We estimated the difference between pre- STARD and post-

129 STARD slopes and the yearly mean effect after STARD publication. Durbin-Watson test was  
130 used to test the residual independence.

131 Only two-tailed tests were used and p-values less than 0.05 was taken as to be statistically  
132 significant. The analysis was conducted using IBM SPSS v16.0 (Armonk, New York, U.S).

## 133 **RESULTS**

134 Seventy-six (76) articles were downloaded and their data extracted from Indian Journal of  
135 Medical Research (IJMR) for the period of 1995-2013. A complete list of the articles used here  
136 for analysis is available from the first author. The percentage of articles meeting each of the 28  
137 criteria (Table 1) for the whole timeline (1995-2013) is presented in Table 2.

### 138 **Descriptives**

#### 139 **STARD: Introduction**

140 In the years before the STARD release around 29 %(10/35) articles identified themselves as  
141 diagnostic accuracy studies whereas post STARD around 42.5% (17/41) articles identified them  
142 so. However, we found this difference to be statistically insignificant ( $\chi^2 = 0.009$ ,  $p = 0.9243$ ).

143 Around 42.9 %( 15/35) articles had clear aims and stated the research questions clearly but this  
144 figure didn't change post-STARD 44 %( 18/41).

#### 145 **STARD: Methods**

146 The method section of the STARD checklist in Table 1 has been divided into various subsections:  
147 participants, test methods and statistical methods. There were no changes observed both in pre-  
148 and post STARD period in regards to description of study population ( $\chi^2 = 0.567$ ,  $p = 0.1158$ ),  
149 participant recruitment ( $\chi^2 = 0.172$ ,  $p = 0.6784$ ), adequate sampling ( $\chi^2 = 0.421$ ,  $p = 0.2447$ ),  
150 sample size calculation, description of data collection ( $\chi^2 = 0.386$ ,  $p = 0.5345$ ), description of  
151 reference standard and its underlying rationale ( $\chi^2 = 0.357$ ,  $p = 0.55$ ) and description of the  
152 technical specifications ( $\chi^2 = 0.22$ ,  $p = 0.0719$ ). In statistical methods, no statistically significant  
153 change was observed in reporting of the methods for calculating or comparing measures of  
154 diagnostic accuracy, and the statistical methods used to quantify uncertainty ( $\chi^2 = 0.029$ ,  $p =$   
155 0.1158).

156 However, significant improvement in mentioning the software used to conduct the analysis was  
157 found in the post-STARD period as compared to the pre-STARD period ( $\chi^2 = 9.122$ ,  $p = 0.0014$ ).  
158 Also, in terms of description of participant sampling, post-STARD period saw a significant  
159 change ( $\chi^2 = 5.712$ ,  $p = 0.0169$ ).

#### 160 **STARD: Results**

161 In regards to the description of results in diagnostic studies (Item nos. in Table 1: 17-21 and 23-  
162 27) within IJMR no statistical change was observed between pre-and post STARD period.  
163 However, there was a significant change ( $p = 0.0045$ ) in post-STARD period for the reporting of  
164 cross tabulation of the results of the index tests by the results of the reference standard; for  
165 continuous results, the distribution of the test results by the results of the reference standard.  
166 Changes in these key items within STARD between pre-post periods is presented in Figure 1.

#### 167 **STARD: Discussion**

168 A major change in this section has been that post-STARD, increasingly articles have been  
169 discussing the clinical applicability of study findings ( $\chi^2 = 9.704$ ,  $p = 0.0018$ ).

#### 170 **Interrupted Time Series Analyses**

171 The above analyses use scores averaged over the pre-post STARD period which were then  
172 compared for any statistically significant changes. As mentioned before, a majority of review  
173 literature on various guidelines use such kind of average based statistics. Here, we used an  
174 interrupted time-series analyses which can detect whether STARD publication had a significant  
175 effect than the underlying trend [17]. Here we considered two periods: pre (1993-2002) and post-  
176 STARD (2004-2013) period.

177 In the pre STARD period, the mean score increased non-significantly ( $p = 0.124$ ). This trend did  
178 not change significantly after publication of the STARD statement until 2010 ( $p = 0.067$  for year  
179 2010). However, from that point of time onwards we see there is a significant change in the mean  
180 scores ( $\beta_3 = 0.215 \pm 0.068$ ,  $p = 0.034$ ). In table 3 values for the baseline trend and changes after  
181 STARD statement publication is provided.

## 182 **DISCUSSIONS**



183 With the publication of many diagnostic studies in medical journals, it has become quite  
184 important to adhere to publishing standards like STARD, CONSORT, and STROBE etc.  
185 Publishing standards allow us to establish a benchmark against which every published article can  
186 measure up. In this study, we have tried to measure the actual success of a publishing standard  
187 (STARD) in improving the reporting quality of diagnostic studies. For this purpose, we used a  
188 major medical journal IJMR which has a long illustrious history among medical journals.

189 Several studies have previously studied the impact of reporting guidelines/statements like  
190 CONSORT, STARD or STROBE. All of them have suggested that using the statement might  
191 improve the overall reporting of published studies [Moher et al., 2001; Hopewell et al., 2010;  
192 Kane et al., 2007]. However, all these studies usually use the uncontrolled version of before-after  
193 study design. Previous published evidence have shown that such uncontrolled before-after  
194 analysis which tends to compare a pre-and post-time around an intervention may in turn lead us  
195 to overestimate the effect of the said intervention [Eccles et al., 2003]. To take into this account,  
196 we used an interrupted time-series analyses. It is considered a very powerful statistical method  
197 for distinguishing the underlying trend from the actual effects of a given intervention [Hopewell  
198 et al., 2010; Kane et al., 2007, Lopez et al., 2017]. Hence, a well-designed time series analysis  
199 has the potential to increase the confidence with which the effect estimate can be ascribed to the  
200 intervention in question. This however has a drawback as we cannot separate any other effects  
201 which might occur at the same time as the intervention [Eccles et al., 2003; Ramsay et al., 2003].  
202 The one major factor which can improve the quality of interrupted-time series analyses is the  
203 number of data points collected before and after intervention [Hopewell et al., 2010; Kane et al.,  
204 2007]. In the present study, pre-and post-STARD period both have sufficient data points in  
205 accordance with the recommendations from Cochrane Effective Practice and Organization of  
206 Care group [Moher et al., 2001].

## 207 **CONCLUSIONS**

208 We conclude that STARD checklist had a statistically significant impact on the reporting quality  
209 of diagnostic studies published in India. Our results show that this general improvement would in  
210 general lead to better reporting quality of diagnostic accuracy studies if STARD is made an  
211 important part of the article submission process in Indian journals. STARD checklist and its

212 extensions, provide a vital tool for researchers not only to use as a guideline for proper reporting  
213 but also to conduct diagnostic studies.

214 We feel, there is a need to continuously educate the medical science professionals regarding  
215 formulating research questions properly using correct statistical techniques and reporting required  
216 results including testing the validity of assumptions of those techniques.

## 217 REFERENCES

- 218 1. Griner PF, Mayewski RJ, Mushlin AI, Greenland P. Selection and interpretation of  
219 diagnostic tests and procedures. Principles and applications. *Ann Intern Med* 1981; 94:  
220 557–92.
- 221 2. Metz CE. Basic principles of ROC analysis. *Semin Nucl Med* 1978; 8: 283–98.
- 222 3. Sackett DL, Haynes RB, Guyatt GH, Tugwell T. The selection of diagnostic tests. In:  
223 *Clinical Epidemiology. A Basic Science for Clinical Medicine*. 2nd ed. London: Little,  
224 Brown, 1991; 47–57.
- 225 4. Lijmer JG, Mol BW, Heisterkamp S et al. Empirical evidence of design-related bias in  
226 studies of diagnostic tests. *JAMA* 1999;282: 1061–6
- 227 5. Reid MC, Lachs MS, Feinstein AR. Use of methodological standards in diagnostic test  
228 research. Getting better but still not good. *JAM A* 1995;274:645–51.
- 229 6. Plint AC, Moher D, Morrison A, et al. Does the CONSORT checklist improve the quality  
230 of reports of randomised controlled trials? A systematic review. *Med J Aust*  
231 2006;185:263–7.
- 232 7. Moher D, Jones A, Lepage L. Use of the CONSORT statement and quality of reports of  
233 randomized trials: a comparative before-and-after evaluation. *JAMA* 2001;285:1992–5.
- 234 8. Turner L, Shamseer L, Altman DG, et al. Consolidated standards of reporting trials  
235 (CONSORT) and the completeness of reporting of randomised controlled trials (RCTs)  
236 published in medical journals. *Cochrane Database Syst Rev* 2012;11:MR000030.

- 237 9. Bossuyt PM. STARD statement: still room for improvement in the reporting of diagnostic  
238 accuracy studies. *Radiology* 2008;248:713–14.
- 239 10. Smidt N, Rutjes AW, van der Windt DA, et al. The quality of diagnostic accuracy studies  
240 since the STARD statement: has it improved? *Neurology* 2006;67:792–7.
- 241 11. Wilczynski NL. Quality of reporting of diagnostic accuracy studies: no change since  
242 STARD statement publication—before-and-after study. *Radiology* 2008;248:817–23.
- 243 12. Shrouf PE, Fleiss JL. (1979) Intraclass correlations: uses in assessing reliability. *Psychol*  
244 *Bull.* 86:420–8
- 245 13. Eccles M, Grimshaw J, Campbell M, Ramsay C. (2003) Research designs for studies  
246 evaluating the effectiveness of change and improvement strategies. *Qual Saf Health Care*  
247 12: 47–52.
- 248 14. Ramsay CR, Matowe L, Grilli R, Grimshaw JM, Thomas RE. (2003) Interrupted time  
249 series designs in health technology assessment: lessons from two systematic reviews of  
250 behavior change strategies. *Int J Technol Assess Health Care* 19: 613–623.
- 251 15. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. (2002) Segmented regression  
252 analysis of interrupted time series studies in medication use research. *J Clin Pharm Ther*  
253 27: 299–309
- 254 16. Group: CEPaOoc. epoc.cochrane website. Available:  
255 [http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/21%20Interrupted%20time](http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/21%20Interrupted%20time%20series%20analyses%202013%2008%2012_1.pdf)  
256 [%20series%20analyses%202013%2008%2012\\_1.pdf](http://epoc.cochrane.org/sites/epoc.cochrane.org/files/uploads/21%20Interrupted%20time%20series%20analyses%202013%2008%2012_1.pdf). Published: December 12, 2009.  
257 Updated: October 15, 2014. Accessed July 29, 2017.
- 258 17. Moher D, Jones A, Lepage L. (2001) Use of the CONSORT statement and quality of  
259 reports of randomized trials: a comparative before-and-after evaluation. *JAMA* 285:  
260 1992–1995.
- 261 18. Hopewell S, Dutton S, Yu LM, Chan AW, Altman DG. (2010) The quality of reports of  
262 randomised trials in 2000 and 2006: comparative study of articles indexed in PubMed.  
263 *BMJ* 340: c723.
- 264 19. Kane RL, Wang J, Garrard J. (2007) Reporting in randomized clinical trials improved  
265 after adoption of the CONSORT statement. *J Clin Epidemiol.* 60:241–249

- 266 20. Lopez Bernal J., Cummins S., Gasparini A. 2016. Interrupted time series regression for  
267 the evaluation of public health interventions: a tutorial. *International Journal of*  
268 *Epidemiology*:dyw098. DOI: 10.1093/ije/dyw098

**Table 1** (on next page)

STARD checklist for the reporting of studies of diagnostic accuracy

<b>Section and Topic</b>	<b>Item Number</b>	<b>Description</b>
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity')
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.
METHODS		
Participants	3	Describe the study population: The inclusion and exclusion criteria, setting and locations where the data were collected.
	4	Describe participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?
	5	Describe participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in items 3 and 4? If not, specify how participants were further selected
	6	Describe data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?

	7	Was the sampling adequate?
	8	Sampling size calculation was done
Test methods	9	Describe the reference standard and its rationale
	10	Describe technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard
	11	Describe definition of and rationale for the units, cutoffs and/or categories of the results of the index tests and the reference standard
	12	Describe the number, training and expertise of the persons executing and reading the index tests and the reference standard
	13	Describe whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.
Statistical Methods	14	Describe methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals)
	15	Describe methods for calculating test reproducibility, if done
	16	16. State which software was used for analysis
RESULTS		
Participants	17	Report when study was done, including beginning and

		ending dates of recruitment
	18	Report clinical and demographic characteristics of the study population (e.g. age, sex, spectrum of presenting symptoms, comorbidity, current treatments, recruitment centers)
	19	Report the number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or the reference standard; describe why participants failed to receive either test (a flow diagram is strongly recommended).
Test Results	20	Report time interval from the index tests to the reference standard, and any treatment administered between.
	21	Report distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.
	22	Report a cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.
	23	Report any adverse events from performing the index tests or the reference standard.
Estimates	24	Report estimates of diagnostic accuracy and measures of statistical uncertainty



		(e.g. 95%confidence intervals)
	25	Report how indeterminate results, missing responses and outliers of the index tests were handled
	26	Report estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done
	27	Report estimates of test reproducibility, if done.
DISCUSSION	28	Discuss the clinical applicability of the study findings

**Table 2** (on next page)

Comparison of correctly reported items between two periods (pre and post-STAR<sup>D</sup>)

Correct use of  $n$  (%): for each item,  $n$  is the number of articles reporting the item correctly and the percentage =  $n/\text{the number of papers reporting the items} \times 100\%$ ; for each,  $n$  is the number of articles with the reported item and the percentage =  $n/\text{the number of papers reporting the items} \times 100\%$ . For cells with no value in chi-square column, the p-value was obtained via Fisher's Test

Items in checklist	Correct use pre-STAR n(%)	Correct use post-STAR n(%)	X <sup>2</sup>	P-value
<b>TITLE/ABSTRACT/ KEYWORDS</b>				
1. Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity')	10(29%)	17(42.5%)	1.572	0.2099
<b>INTRODUCTION</b>				
2. State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	15(42.9%)	18(44%)	0.008	0.927
<b>METHODS: Participants</b>				
3. Describe the study population: The inclusion and exclusion criteria, setting and locations where the data were collected.	1(2.9%)	6(14.6%)	-	0.1158
4. Describe participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	13(42%)	11(27.5%)	0.172	0.6784
5. Describe participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in items 3 and 4? If not, specify how participants were further selected	1(3.57%)	9(25.7%)	5.712	0.0169
6. Was the sampling adequate?	0(0%)	3(7.3%)	-	0.2447
7. Sampling size calculation was done	0(0%)	1(2.44%)	-	NA

8. Describe data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	17(48.57%)	17(42%)	0.386	0.5345
<b>METHODS: Test methods</b>				
9. Describe the reference standard and its rationale	13(37%)	18(44%)	0.357	0.55
10. Describe technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard	7(20%)	2(4.9%)	-	0.0719
11. Describe definition of and rationale for the units, cutoffs and/or categories of the results of the index tests and the reference standard	0(0%)	0(0%)	-	NA
12. Describe the number, training and expertise of the persons executing and reading the index tests and the reference standard	0(0%)	0(0%)	-	NA
13. Describe whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	-	0(0%)	-	NA
<b>METHODS: Statistical Methods</b>				
14. Describe methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95%confidence	1(2.9%)	6(14.7%)	0.029	0.1158
15. Describe methods for calculating test reproducibility, if done	0(0%)	2(50%)	-	0.4286
16. State which software was used for analysis	0(0%)	10(24.4%)	-	0.0014

<b>RESULTS: Participants</b>				
17. Report when study was done, including beginning and ending dates of recruitment	0(0%)	0(0%)	-	NA
18. Report clinical and demographic characteristics of the study population (e.g. age, sex, spectrum of presenting symptoms, comorbidity, current treatments, recruitment centers)	1(2.9%)	7(17%)	-	0.0627
19. Report the number of participants satisfying the criteria for inclusion that did or did not undergo the index tests and/or the reference standard; describe why participants failed to receive either test (a flow diagram is strongly recommended).	0(0%)	0(0%)	-	NA
<b>RESULTS: Test Results</b>				
20. Report time interval from the index tests to the reference standard, and any treatment administered between.	0(0%)	0(0%)	-	NA
21. Report distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	0(0%)	1(2.7%)	-	NA
22. Report a cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	2(6.25%)	14(34.14%)	-	0.0045
23. Report any adverse events from performing the index tests or the	0(0%)	0(0%)	-	NA

reference standard.				
---------------------	--	--	--	--

<b>RESULTS: Estimates</b>				
24. Report estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95%confidence intervals)	1(2.85%)	6(14.6%)	-	NA
25. Report how indeterminate results, missing responses and outliers of the index tests were handled	0(0%)	0(0%)	-	NA
26. Report estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done	0(0%)	0(0%)	-	NA
27. Report estimates of test reproducibility, if done	0(0%)	0(0%)	-	NA
<b>DISCUSSION</b>				
28. Discuss the clinical applicability of the study findings	6(17.4%)	22(54%)	9.704	0.0018

**Table 3** (on next page)

Parameter estimates from the Interrupted time-series model predicting the mean yearly score per article

	<b>Estimated Coefficient (Standard deviation)</b>	<b>P-value</b>
<b>Interrupted time-series model</b>		
1st segment (pre-STARD, 1993 to 2002)		
Intercept	0.155(0.026)	0.004
Baseline Trend	0.038(0.011)	0.028
2nd segment (post- STARD, 2004 to 2013)		
Trend Change	0.215(0.068)	0.034



# Figure 1

Comparison of certain scores before and after STARD publication (1993-2013)

This figure gives a gist of the average mean score of all articles for certain selected items for which a significant change was observed in post-STARD period

